Lea Arregui Nordahl Christoffersen

Lea Arregui Nordahl Christoffersen

Auto-generated profile, based on publicly available information

Lea Arregui Nordahl Christoffersen

Institute of Biological Psychiatry, Mental Health Services, Amager and Hvidovre Hospital, Copenhagen University Hospital, Roskilde, Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Environmental Research
Verified
Journal Article
Closed access
TMThit A. Mørck
Thit A. Mørck
FNFlemming Nielsen
Flemming Nielsen
JNJeanette K.S. Nielsen
Jeanette K.S. Nielsen
JJJanne F. Jensen
Janne F. Jensen
PHPernille W. Hansen
Pernille W. Hansen
Lisbeth E. KnudsenLisbeth E. Knudsen
Lisbeth E. Knudsen

13 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FSFabian . Streit
Fabian . Streit
SASwapnil Awasthi
Swapnil Awasthi
AHAlisha Sm Hall
Alisha Sm Hall
ABAlice Braun
Alice Braun
MNMaria Niarchou
Maria Niarchou
NAN A
N A
We conducted the largest genome-wide meta-analysis of borderline personality disorder (BPD) to date, with a discovery sample of 12,339 cases and 1,041,717 controls, and a replication study of 685 cases and 107,750 controls (all participants of European ancestry). We identified 11 independent associated genomic loci, and nine risk genes in the gene-based analysis. We observed a single-nucleotide polymorphism (SNP) heritability of 17.3% and derived polygenic scores (PGS) predicted 4.6% of the phenotypic variance in BPD on the liability scale. BPD showed the strongest positive genetic correlations with GWAS of posttraumatic stress disorder, depression, attention deficit hyperactivity disorder, antisocial behavior, and measures of suicide and self-harm. Phenome-wide association analyses using BPD-PGS confirmed these associations and additionally revealed associations with general medical conditions including obstructive pulmonary disease and diabetes. The present analyses highlight BPD as a polygenic disorder, with the genetic risk showing substantial overlap with psychiatric and physical health conditions.

1 September 2021 in Alcohol
Verified
Journal Article
Closed access
LCLea Arregui Nordahl Christoffersen
Lea Arregui Nordahl Christoffersen
EMErik Lykke Mortensen
Erik Lykke Mortensen
UBUlrik Becker
Ulrik Becker
MOMerete Osler
Merete Osler
HSHolger Jelling Sørensen
Holger Jelling Sørensen
TFTrine Flensborg-Madsen
Trine Flensborg-Madsen

9 July 2025 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Open access
MHMalthe E. B. Hviid
Malthe E. B. Hviid
LCLea A. N. Christoffersen
Lea A. N. Christoffersen
MKMette K. Klausen
Mette K. Klausen
TBThorsten Brodersen
Thorsten Brodersen
OPOle Birger Vesterager Pedersen
Ole Birger Vesterager Pedersen
AFAnders Fink‐Jensen
Anders Fink‐Jensen
Background: Alcohol use disorder (AUD) has been associated with inflammation, metabolic syndrome, and increased risk of all‐cause mortality. This study aimed to compare the pro‐inflammatory and metabolic biomarker profiles in individuals with AUD with individuals without AUD, and to evaluate the effect of exenatide on these biomarkers in individuals with AUD. Methods: Serum concentrations of 25 biomarkers (interferon‐γ [IFN‐γ], tumor necrosis factor‐α [TNF‐α], interleukin (IL)‐1β, IL‐2, IL‐4, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐13, monocyte chemoattractant protein‐1 [MCP‐1], C‐peptide, gastric inhibitory polypeptide [GIP], glucagon‐like peptide [GLP‐1], glucagon, insulin, leptin, pancreatic polypeptide [PP], adiponectin, high sensitivity C‐reactive protein [hsCRP], fibroblast growth factor 21 [FGF‐21], total cholesterol [CHOL], high‐density lipoprotein [HDL], low‐density lipoprotein [LDL], and triglycerides [TG]) from individuals with AUD were measured at baseline and after 26 weeks of treatment with the GLP‐1 receptor agonist (GLP‐1RA) exenatide once‐weekly or placebo, using multiplexed immunoassays, enzyme‐linked immunosorbent assay (ELISA), and line immunoassays. Serum samples from 23 individuals with no record of AUD or treatment with a GLP‐1RA were measured once for comparison with individuals with AUD. Results: IL‐6 (1.56 vs. 0.62 pg/mL), hsCRP (3.30 vs. 1.34 mg/L), and FGF‐21 (1794.97 vs. 306.11 pg/mL) were significantly higher, whereas GIP (63.06 vs. 111.07 pg/mL) was significantly lower in individuals with AUD ( n = 124) than in those without AUD ( n = 23). No significant changes in biomarker levels were observed after treatment with exenatide ( n = 40) compared with treatment with placebo ( n = 37). Conclusion: Our findings support the well‐established link between AUD and inflammation. However, treatment with the GLP‐1 receptor agonist exenatide did not impact pro‐inflammatory and metabolic biomarkers.

18 September 2018 in Chronic Illness
Verified
Journal Article
Closed access
LCLea An Christoffersen
Lea An Christoffersen
AHAnne K Hansen
Anne K Hansen
RPRegitze As Pals
Regitze As Pals
IWIngrid Willaing
Ingrid Willaing
VSVolkert Siersma
Volkert Siersma
KOKasper Olesen
Kasper Olesen
To assess the effect of a participatory group-based education programme for individuals with type 2 diabetes, Next Education. In a quasi-experimental study, individuals with type 2 diabetes were recruited from 14 Danish municipalities with a patient education programme. Eight municipalities using Next Education were intervention sites; six control sites used usual group-based education programmes. Data were collected through questionnaires at baseline and at 3 and 12 months after programmes ended. Changes in quality of life (EQ-5D-5L), diabetes-related emotional distress (PAID-5), physical activity, diet, foot care and sense of coherence (SOC-13) were assessed in generalised linear mixed models. At baseline, 310 participants (52.6% females, mean age 62.5 years [SD = 10.7] and a mean duration of type 2 diabetes of 6.9 years [SD = 8.4]) participated in Next Education (n = 234) or group-based education (n = 76) at control sites. Compared with participants at control sites, participants at intervention sites had significantly larger sense of coherence scores at 3 (9.4%, p = 0.03) and 12 (9.8%, p = 0.02) months of follow-up. Other measures did not differ significantly between groups. It is likely that person-centeredness and high degrees of user participation at the intervention sites improved sense of coherence among Danes with type 2 diabetes.

17 February 2025 in Journal of Mood & Anxiety Disorders
Verified
Journal Article
Open access
MDMaria Didriksen
Maria Didriksen
HDHilda Daníelsdottir
Hilda Daníelsdottir
MBMarín Dögg Bjarnadóttir
Marín Dögg Bjarnadóttir
COCassie Overstreet
Cassie Overstreet
KCKarmel W. Choi
Karmel W. Choi
ASAndrew J. Schork
Andrew J. Schork
Identifying specific factors affecting psychological resilience could be instrumental in developing new therapeutic strategies for improving and maintaining mental and physical health. To achieve this, an adequate measure of psychological resilience is essential. We studied the psychometric properties of the 10-item Connor-Davidson Resilience Scale (CD-RISC-10) across three population-based cohorts. The study included adult Danish individuals in the Danish Blood Donor Study (DBDS, N = 57,031), and the Icelandic cohorts Stress-And-Gene Analysis cohort (SAGA, N = 27,236), and COVID-19 National Resilience cohort (C19-Resilience, N = 20,373). Exploratory factor analysis revealed a consistent one-factor fit across cohorts. The scale demonstrated good internal consistency (Cronbach's alpha: 0.88–0.90) and longitudinal stability (Spearman correlation coefficients in DBDS: 0.71 across 1.5 years, 0.66 across two years). Mean CD-RISC-10 scores were consistent with previously reported scores in European populations. Lower scores were observed among participants with probable major depressive disorder, and higher scores were found with increasing age. Further evidence for construct validity was revealed as CD-RISC-10 scores moderated the association between financial trouble and depressive symptoms across all cohorts. Psychometric properties of the CD-RISC-10 were similar among women and men. Our findings support the use of the CD-RISC-10 as a reliable and valid unidimensional measure of psychological resilience in Danish and Icelandic populations.